Results 201 to 210 of about 147,109 (307)

Non‐canonical PKG1 regulation in cardiovascular health and disease

open access: yesBritish Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Spectrofluorimetric Method for Sensitive Histamine Detection Using Europium Complexation. [PDF]

open access: yesACS Omega
Kamel KB   +5 more
europepmc   +1 more source

Need to Assess On‐Demand Versus Continuous Treatment in Allergic Rhinitis in ARIA‐EAACI Guidelines

open access: yes
Allergy, EarlyView.
Jean Bousquet   +7 more
wiley   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman   +3 more
wiley   +1 more source

Neuronal and ion channel mechanisms of noxious heat sensing in mammals: A puzzle of sensory physiology and pharmacology

open access: yesBritish Journal of Pharmacology, EarlyView.
Transient receptor potential vanilloid 1 (TRPV1) was the first noxious heat‐sensitive channel discovered. In rodents, its role is robust in the heat response of the cell body of polymodal nociceptors, but surprisingly small in that of the peripheral terminals in the skin.
Gábor Pethő, Peter W. Reeh
wiley   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Home - About - Disclaimer - Privacy